Earnings Summary

Altimmune Inc’s revenue jumped 133.64% since last year same period to $0.04Mn in the Q4 2023. On a quarterly growth basis, Altimmune Inc has generated -89.78% fall in its revenue since last 3-months.

Altimmune Inc’s net profit fell -56.44% since last year same period to $-31.64Mn in the Q4 2023. On a quarterly growth basis, Altimmune Inc has generated -53.07% fall in its net profits since last 3-months.

Altimmune Inc’s net profit margin fell -565.08% since last year same period to -85516.22% in the Q4 2023. On a quarterly growth basis, Altimmune Inc has generated -1397.6% fall in its net profit margins since last 3-months.

Altimmune Inc’s earning per share (EPS) estimates for the current quarter stand at -0.38 - a 11.63% jump from last quarter’s estimates.

Altimmune Inc’s earning per share (EPS) estimates for the current year stand at -0.38.

Altimmune Inc’s earning per share (EPS) fell -25.58% since last year same period to -0.54 in the Q4 2023. This indicates that the Altimmune Inc has generated -25.58% annual rate of fall in its earning per share (EPS) in the last 4 quarters.

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Altimmune Inc’s return on assets (ROA) stands at -0.25.

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Altimmune Inc’s return on equity (ROE) stands at -0.47.